Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067

Journal of Clinical Lipidology

Volumn 1, Issue 4, 2007, Pages 271-279

  Davidson, Michael H ^a,b   Smith, Joseph ^c   Scott, Robert ^c   Small, Robert ^c   Choi, Jasmine ^c   Ishida, Brian Y ^d   Kane, John P ^d  

^a RUSH MEDICAL COLLEGE   (United States)

^b RADIANT RESEARCH   (United States)

^c AtheroGenics Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AGI 1067; Antiatherosclerotic; Antioxidant activity; High density lipoprotein; Vascular oxidative inflammatory cascade inhibitor

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROBUCOL SUCCINATE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; LIPID OXIDATION; MALE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 34548438424     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.07.005     Document Type: Article

References (31)

1. Franks A.M., and Gardner S.F. AGI-1067: a novel vascular protectant for prevention of restenosis. Ann Pharmacother 40 (2006) 66-73
2. Tardif J.C. Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am J Cardiol 91 (2003) 41A-49A
3. Meng C.Q., Somers P.K., Rachita C.L., et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 12 (2002) 2545-2548
4. Sundell C.L., Somers P.K., Meng C.Q., et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther 305 (2003) 1116-1123
5. Tardif J.C., Gregoire J., Schwartz L., et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 107 (2003) 552-558
6. Wasserman M.A., Sundell C.L., Kunsch C., Edwards D., Meng C.Q., and Medford R.M. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 91 (2003) 34A-40A
7. Tardif J. Antioxidants: the good, the bad and the ugly. Can J Cardiol 22 (2006) 61B-65B
8. Tardif J.C., Gregoire J., L'allier P.L., et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis (2007) [Epub ahead of print]
9. Kozarsky K.F., Donahee M.H., Glick J.M., Krieger M., and Rader D.J. Gene transfer and hepatic overexpression of the HDL receptor SR-B1 reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 20 (2000) 721-727
10. Kulkarni K.R., Garber D.W., Jones M.K., and Segrest J.P. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res 36 (1995) 2291-2302
11. Kulkarni K.R., Marcovina S.M., Krauss R.M., Garber D.W., Glasscock A.M., and Segrest J.P. Quantification of HDL2 and HDL3 cholesterol by the vertical auto profile-II (VAP-II) methodology. J Lipid Res 38 (1997) 2353-2364
12. Chu J.W., Abbasi F., Kulkarni K.R., et al. Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology. Clin Chem 49 (2003) 1014-1017
13. Kunitake S.T., Jarvis M.R., Hamilton R.L., and Kane J.P. Binding of transition metals of apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low-density lipoproteins. Proc Natl Acad Sci USA 89 (1992) 6993-6997
14. Hirano K., Ikegami C., Tsujii K., et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 25 (2005) 2422-2427
15. Hirano K., Yamashita S., and Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 11 (2000) 589-596
16. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., and Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 (1995) 488-493
17. Kuzuya M., Naito M., Funaki C., Hayashi T., Asai K., and Kuzuya F. Probucol prevents oxidative injury to endothelial cells. J Lipid Res 32 (1991) 197-204
18. Roberts M.J., Young I.S., Trouton T.G., et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 336 (1990) 143-145
19. Iuliano L., Pratico D., Greco C., et al. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 37 (2001) 76-80
20. McLean L.R., Thomas C.E., Weintraub B., and Hagaman K.A. Modulation of the physical state of cellular cholesteryl esters by probucol. J Biol Chem 267 (1992) 12291-12298
21. Kunsch C., and Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85 (1999) 753-766
22. ARISE-Aggressive Reduction of Inflammation Stops Events. Reduction of vascular inflammation and coronary atherosclerosis with AGI-1067, a v-protectant, reduces cardiovascular events in patients with coronary artery disease. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00066898. Accessed May 10, 2007.
23. Klerkx A.H., El Harchaoui K., van der Steeg W.A., et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 26 (2006) 706-715
24. Zhang Y., Da Silva J.R., Reilly M., Billheimer J.T., Rothblat G.H., and Rader D.J. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115 (2005) 2699-2701
25. Noto H., Kawamurab M., Hashimoto Y., et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 171 (2003) 131-136
26. Navab M., Anantharamaiah G.M., Hama S., et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25 (2005) 1426-1432
27. Hong S.C., Zhao S.P., and Wu Z.H. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol 47 (2006) 77-81
28. James R.W., Leviev I., Ruiz J., Passa P., Froguel P., and Garin M.C. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49 (2000) 1390-1393
29. Leviev I., Poirier O., Nicaud V., et al. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 161 (2002) 463-467
30. Sasahara M., Raines E.W., Chait A., et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol: is the extent of atherosclerosis related to resistance of LDL to oxidation?. J Clin Invest 94 (1994) 155-164
31. Sawayama Y., Shimizu C., Maeda N., et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39 (2002) 610-616